Hypofractionation for Prostate Cancer in Africa: A Feasibility Study

Hypofractionated radiotherapy (HFRT) is a technique that delivers a higher radiation dose per treatment fraction over a shorter overall number of fractions, thus reducing the number of radiotherapy visits required to complete a course of radiation therapy. HFRT significantly alleviates the burden of transportation, accommodation, and income loss for patients while mitigating the strain on already limited healthcare personnel and infrastructure resources. Several randomized studies conducted in Europe and the USA have demonstrated that HFRT for prostate cancer is non-inferior to conventional radiotherapy in terms of toxicity and treatment outcomes. HypoAfrica Prostate Cancer is a multi-center study that aims to explore the feasibility of implementing moderate HFRT for the treatment of localized prostate cancer in Africa. In particular, this study will evaluate the gastrointestinal and genitourinary toxicities in prostate cancer patients for up to two years post-completion of HFRT.

NCT Number	NCT06950307
Lead Sponsor	Muhimbili University of Health and Allied Sciences Collaborators: Inkosi Albert Luthuli Central Hospital, Erasmus Medical Center, Dana-Farber Cancer Institute, Nigeria Sovereign Investment Authority-Lagos University Teaching Hospital Cancer Center (NLCC)
Conditions	Prostate Cancer
Enrollment	182 participants
Start Date	2021-12-30
Primary Completion	2026-03-01 (estimated)
Study Completion	2029-03-01 (estimated)
Updated on ClinicalTrials.gov	2025-04-30